Navigation Links
Genetics May Determine Antidepressants' Effectiveness

German researchers identify 11 variants that seem to influence outcome

WEDNESDAY, Jan. 23 (HealthDay News) -- Genetic variations that predict patient response to the two common antidepressant drugs citalopram (brand name Celexa) and venlafaxine (Effexor) have been identified by German researchers.

The team at the Max Planck Institute of Psychiatry in Munich found that 11 variants in the gene for a protective transporter protein called P-gp, which removes drugs and other substances from the brain, compromise the effectiveness of these two drugs.

In the first part of the study, the researchers knocked out genes for P-gp in mice and gave them antidepressants. They found that brain concentrations of citalopram and venlafaxine were regulated by P-gp, indicating that the antidepressants were "substrates" of the transporter protein.

Next, the team analyzed 443 people on antidepressants for genetic variants that correlated with reduced efficacy of the two antidepressants.

"To our knowledge, our results provide for the first time evidence that genetic variants in the (gene for P-gp) account for differences in the clinical efficacy of antidepressants, most likely by influencing their access to the brain," the researchers wrote.

The findings, published in the Jan. 24 issue of the journal Neuron, suggest that genetic testing could help predict how individual patients would react to specific antidepressants, the researchers said.

They added that genetic tests may also help predict the effectiveness of any drugs used to treat neurological diseases.

"The general conclusion to be drawn is that any drug treatment administered to treat CNS (central nervous system) diseases should be analyzed for its P-gp substrate status, which can be determined by using knockout mice. From a clinical point of view, the findings warrant that patients receiving a drug that is a P-gp substrate for the treatment of brain diseases are genotyped to exclude the possibility that a patient receives a drug that fails to enter the CNS to an extent required for efficacy," the study authors wrote.

Future development of antidepressants should take into account whether new drugs are transported by P-gp, and clinical trials of antidepressant drugs need to factor in the P-gp genetic status of participants, the researchers recommended.

More information

The U.S. National Institute of Mental Health has more about depression.

-- Robert Preidt

SOURCE: Cell Press, news release, Jan. 23, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Genetics Influence Blood Pressure Medications
2. People with anorexia less likely to be blamed when biology, genetics explained
3. Top10 research advances include studies on genetics and stem cell research, stents
4. Heart attack risk from smoking due to genetics
5. Genetics May Boost Mexican-Americans Risk for Alcoholism
6. Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Assessment of Its Phase I/II Trial of tgAAC94 for Inflammatory Arthritis
7. Researchers develop powerful tool to study the genetics of inflammation
8. deCODE genetics to Webcast Presentation at Piper Jaffray Annual Healthcare Conference
9. deCODE genetics to Webcast Presentation at Lazard Capital Markets Annual Healthcare Conference
10. Genetics and Risk, This Week on Your Cancer Today(TM)
11. CellCyte Genetics Corp. Appoints Tony Colasin as Director of Business Development
Post Your Comments:
Related Image:
Genetics May Determine Antidepressants' Effectiveness
(Date:11/24/2015)... ... November 24, 2015 , ... ... been designated an Aetna Institute of Quality® Bariatric Surgery Facility for treating individuals ... and cost of health care services available to its members to help them ...
(Date:11/24/2015)... IL (PRWEB) , ... November 24, 2015 , ... Dr. Rodney E. Willey , ... His new venture, Koala Center for Sleep Disorders, provides treatment for snoring and sleep ... who have opened a Koala Center for Sleep Disorders in the US, one of four ...
(Date:11/24/2015)... Diego, CA (PRWEB) , ... November 24, 2015 ... ... the Silver&Fit® Exercise and Healthy Aging Program have announced their ... referral service. , “American Specialty Health Fitness is proud to have the MFN ...
(Date:11/24/2015)... N.Y. (PRWEB) , ... November 24, 2015 , ... Autism ... Tuesday, the global movement driven by social media and the generosity of people around ... then encourage their social media networks to give – and share the personal stories ...
(Date:11/24/2015)... Miami, FL (PRWEB) , ... November 24, 2015 ... ... manufacturer and engineer of patented products, announces Innovative Blending, a household invention that ... go. , "The Juice & Smoothie Bars market is worth $2 billion," says ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... NEWS, Va. , Nov. 24, 2015  DILON ... they have signed an agreement for DILON to distribute ... geographies across the globe. The signing of this distribution agreement ... Discovery NM750b Molecular Breast Imaging system and is considered ... to provide better healthcare solutions for clinicians and their ...
(Date:11/24/2015)... , Nov. 24, 2015 Avery Biomedical ... is pleased to announce the appointment of Anders ... Dr. Jonzon ... cardiology at Children,s Hospital, Uppsala University, Uppsala and Children,s ... 1984-1986, he was a fellow at the Cardiovascular Institute ...
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
Breaking Medicine Technology: